Literature DB >> 28108629

Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Jingjiao Zhou1,2, Zhaoxia Qu3,2, Fan Sun1,2, Lei Han1,2, Liwen Li1,2, Shapei Yan1, Laura P Stabile1,4, Lin-Feng Chen5, Jill M Siegfried1,4, Gutian Xiao3,2.   

Abstract

One of the most fundamental and challenging questions in the cancer field is how immunity in patients with cancer is transformed from tumor immunosurveillance to tumor-promoting inflammation. Here, we identify the transcription factor STAT3 as the culprit responsible for this pathogenic event in lung cancer development. We found that antitumor type 1 CD4+ T-helper (Th1) cells and CD8+ T cells were directly counter balanced in lung cancer development with tumor-promoting myeloid-derived suppressor cells (MDSCs) and suppressive macrophages, and that activation of STAT3 in MDSCs and macrophages promoted tumorigenesis through pulmonary recruitment and increased resistance of suppressive cells to CD8+ T cells, enhancement of cytotoxicity toward CD4+ and CD8+ T cells, induction of regulatory T cell (Treg), inhibition of dendritic cells (DC), and polarization of macrophages toward the M2 phenotype. The deletion of myeloid STAT3 boosted antitumor immunity and suppressed lung tumorigenesis. These findings increase our understanding of immune programming in lung tumorigenesis and provide a mechanistic basis for developing STAT3-based immunotherapy against this and other solid tumors. Cancer Immunol Res; 5(3); 257-68. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28108629      PMCID: PMC5334370          DOI: 10.1158/2326-6066.CIR-16-0073

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  48 in total

Review 1.  Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention.

Authors:  Stephen S Hecht
Journal:  Lancet Oncol       Date:  2002-08       Impact factor: 41.316

2.  Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice.

Authors:  Elizabeth F Redente; David J Orlicky; Ronald J Bouchard; Alvin M Malkinson
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters.

Authors:  Guoliang Qing; Zhaoxia Qu; Gutian Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-15       Impact factor: 11.205

4.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice.

Authors:  B E Clausen; C Burkhardt; W Reith; R Renkawitz; I Förster
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

Review 5.  Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers.

Authors:  Carr J Smith; Thomas A Perfetti; Judy A King
Journal:  Inhal Toxicol       Date:  2006-08       Impact factor: 2.724

6.  Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.

Authors:  Chien-Ying Liu; Yu-Min Wang; Chih-Liang Wang; Po-Hao Feng; How-Wen Ko; Yun-Hen Liu; Yi-Cheng Wu; Yen Chu; Fu-Tsai Chung; Chih-Hsi Kuo; Kang-Yun Lee; Shu-Min Lin; Horng-Chyuan Lin; Chun-Hua Wang; Chih-Teng Yu; Han-Pin Kuo
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

7.  PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation.

Authors:  Pengrong Yan; Jing Fu; Zhaoxia Qu; Shirong Li; Takashi Tanaka; Michael J Grusby; Gutian Xiao
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

Review 9.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 10.  Macrophage polarization in tumour progression.

Authors:  Antonio Sica; Paola Larghi; Alessandra Mancino; Luca Rubino; Chiara Porta; Maria Grazia Totaro; Monica Rimoldi; Subhra Kumar Biswas; Paola Allavena; Alberto Mantovani
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

View more
  33 in total

1.  JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.

Authors:  Emily A Irey; Chelsea M Lassiter; Nicholas J Brady; Pavlina Chuntova; Ying Wang; Todd P Knutson; Christine Henzler; Thomas S Chaffee; Rachel I Vogel; Andrew C Nelson; Michael A Farrar; Kathryn L Schwertfeger
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-30       Impact factor: 11.205

2.  NF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion.

Authors:  Liwen Li; Lei Han; Fan Sun; Jingjiao Zhou; Kim C Ohaegbulam; Xudong Tang; Xingxing Zang; Kris A Steinbrecher; Zhaoxia Qu; Gutian Xiao
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

3.  Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.

Authors:  Lei Zhang; Qiaoling Song; Xinxin Zhang; Li Li; Ximing Xu; Xiaohan Xu; Xiaoyu Li; Zhuoya Wang; Yuxi Lin; Xin Li; Mengyuan Li; Fan Su; Xin Wang; Peiju Qiu; Huashi Guan; Yu Tang; Wenfang Xu; Jinbo Yang; Chenyang Zhao
Journal:  Invest New Drugs       Date:  2019-05-14       Impact factor: 3.850

Review 4.  Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis.

Authors:  Qing Bi; Ji-Yue Wu; Xue-Meng Qiu; Jian-Dong Zhang; Ze-Jia Sun; Wei Wang
Journal:  J Immunol Res       Date:  2022-06-13       Impact factor: 4.493

Review 5.  Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies.

Authors:  Konstantinos Rounis; Dimitrios Makrakis; Ioannis Gioulbasanis; Simon Ekman; Luigi De Petris; Dimitris Mavroudis; Sofia Agelaki
Journal:  Life (Basel)       Date:  2022-06-12

6.  The role of exosomal miR-181b in the crosstalk between NSCLC cells and tumor-associated macrophages.

Authors:  Junliang Ma; Shaolin Chen; Yingjie Liu; Hao Han; Ming Gong; Yongxiang Song
Journal:  Genes Genomics       Date:  2022-02-12       Impact factor: 2.164

7.  Prevention of Tobacco Carcinogen-Induced Lung Tumor Development by a Novel STAT3 Decoy Inhibitor.

Authors:  Christian Njatcha; Mariya Farooqui; Abdulaziz A Almotlak; Jill M Siegfried
Journal:  Cancer Prev Res (Phila)       Date:  2020-07-12

8.  Murine Bronchoalveolar Lavage.

Authors:  Fan Sun; Gutian Xiao; Zhaoxia Qu
Journal:  Bio Protoc       Date:  2017-05-20

9.  Isolation of Murine Alveolar Type II Epithelial Cells.

Authors:  Fan Sun; Gutian Xiao; Zhaoxia Qu
Journal:  Bio Protoc       Date:  2017-05-20

10.  Alveolar Macrophages Inherently Express Programmed Death-1 Ligand 1 for Optimal Protective Immunity and Tolerance.

Authors:  Fan Sun; Liwen Li; Yadong Xiao; Alyssa D Gregory; Steven D Shapiro; Gutian Xiao; Zhaoxia Qu
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.